BRCA1 and ovarian carcinoma: A functional HR assay, the recombination Repair CAPacity (RECAP) test, was originally developed to identify HRD in breast cancers [67,92] and more recently ovarian cancers [93], detecting both BRCA1/2-deficient and BRCA1/2-proficient HRD tumours in ex vivo tumour slice cultures.